POPULATION PHARMACOKINETICS OF AMIKACIN IN INTENSIVE-CARE UNIT PATIENTS STUDIED BY NPEM ALGORITHM

被引:16
|
作者
DEBORD, J
PESSIS, C
VOULTOURY, JC
MARQUET, P
LOTFI, H
MERLE, L
LACHSATRE, G
机构
[1] HOP DUPUYTREN,SERV PHARMACOL TOXICOL,F-87042 LIMOGES,FRANCE
[2] HOP DUPUYTREN,SERV REANIMAT POLYVALENTE,F-87042 LIMOGES,FRANCE
[3] FAC PHARM LIMOGES,TOXICOL LAB,F-87025 LIMOGES,FRANCE
关键词
AMIKACIN; POPULATION PHARMACOKINETICS; NPEM ALGORITHM; BAYESIAN ESTIMATION; PREDICTIVE PERFORMANCE;
D O I
10.1111/j.1472-8206.1995.tb00266.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The population pharmacokinetics of amikacin was studied in 40 intensive care unit patients (212 plasma concentrations) by NPEM algorithm using a one-compartment model. The population was best characterized by the following pharmacokinetic parameters: renal clearance relative to creatinine clearance (C-s = 0.96 +/- 0.33), and either the total volume of distribution (V-d = 23.9 +/- 7.01) or the volume of distribution relative to body weight (V-s = 0.36 +/- 0.10 l.kg(-1). The volume of distribution was increased with respect to the usual value of 0.25 l.kg(-1). The statistical distribution of these pharmacokinetic parameters was approximately gaussian, with no significant correlation between volume of distribution and clearance. The medians and standard deviations of C-s and V-s were used as reference population values to estimate the pharmacokinetics of amikacin in a second group of 29 patients by the bayesian method, with two blood samples per patient. For each patient, the fitted parameters were able to predict the plasma concentrations of amikacin during the next 72 h with no significant bias and good precision (2.9 mg.l(-1) for peaks and 0.5 mg.l(-1) for troughs). This study confirms the ability of the NPEM algorithm to provide reference population values for use in bayesian monitoring of aminoglycoside therapy.
引用
收藏
页码:57 / 61
页数:5
相关论文
共 50 条
  • [41] INTENSIVE-CARE - INTERNATIONAL STANDARDS FOR INTENSIVE-CARE UNIT SAFETY
    CRAWFORD, ME
    SORENSEN, MB
    DAHL, JB
    LANCET, 1993, 341 (8852): : 1061 - 1061
  • [42] DOBUTAMINE PHARMACOKINETICS AND PHARMACODYNAMICS IN PEDIATRIC INTENSIVE-CARE PATIENTS
    HABIB, DM
    PADBURY, JF
    ANAS, NG
    PERKIN, RM
    MINEGAR, C
    PEDIATRIC RESEARCH, 1989, 25 (04) : A67 - A67
  • [43] DOBUTAMINE PHARMACOKINETICS AND PHARMACODYNAMICS IN PEDIATRIC INTENSIVE-CARE PATIENTS
    HABIB, DM
    PADBURY, JF
    ANAS, NG
    PERKIN, RM
    MINEGAR, C
    CRITICAL CARE MEDICINE, 1992, 20 (05) : 601 - 608
  • [44] CLINICAL PHARMACOKINETICS OF MIDAZOLAM (M) IN INTENSIVE-CARE PATIENTS
    OLDENHOF, HGJ
    DEJONG, M
    STEENHOEK, A
    JANKNEGT, R
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1987, 9 (03) : 190 - 190
  • [45] EVALUATION OF A BAYESIAN METHOD OF AMIKACIN DOSING IN INTENSIVE-CARE UNIT PATIENTS WITH NORMAL OR IMPAIRED RENAL-FUNCTION
    LACARELLE, B
    GRANTHIL, C
    MANELLI, JC
    BRUDER, N
    FRANCOIS, G
    CANO, JP
    THERAPEUTIC DRUG MONITORING, 1987, 9 (02) : 154 - 160
  • [46] PARENT CARE IN THE INTENSIVE-CARE UNIT
    GREEN, M
    AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1979, 133 (11): : 1119 - 1120
  • [47] THE INTENSIVE-CARE UNIT POPULATION WITHIN THE PROSPECTIVE PAYMENT SCHEME
    GALANES, S
    HARRIS, B
    DULSKI, R
    CHAMBERLIN, W
    HEART & LUNG, 1986, 15 (05): : 515 - 520
  • [48] SEDATION IN THE INTENSIVE-CARE UNIT
    STONE, DJ
    SEMINARS IN ANESTHESIA, 1990, 9 (03): : 162 - 168
  • [49] SLEEP IN THE INTENSIVE-CARE UNIT
    KRACHMAN, SL
    DALONZO, GE
    CRINER, GJ
    CHEST, 1995, 107 (06) : 1713 - 1720
  • [50] THE COST OF AN INTENSIVE-CARE UNIT
    HUNTER, AR
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1981, 25 : 103 - 103